- Current report filing (8-K)
January 21 2011 - 4:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________
FORM
8-K
______________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 20,
2011
______________
Cytomedix,
Inc.
(Exact
name of registrant as specified in its charter)
______________
Delaware
|
01-32518
|
23-3011702
|
(State
or Other Jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
209
Perry Parkway, Suite 7, Gaithersburg, MD 20877
(Address
of Principal Executive Office) (Zip Code)
240-499-2680
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
3.01
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On
January 20, 2011, Cytomedix, Inc., a Delaware corporation (the “Company”)
notified the staff of the NYSE Amex (the “Exchange”) of its intent to withdraw
the request for a hearing, and the Exchange notified the Company that the
Company’s common stock would cease trading on the Exchange with the open of
trading on or about January 25, 2011. The Company’s common stock is expected to
be quoted on the OTC Bulletin Board on or about January 25, 2011; however, there
is no assurance that its over the counter trading application will be approved.
The Company intends to continue to file periodic reports with the SEC pursuant
to the requirements of the Securities Exchange Act of 1934, as
amended.
As
previously reported, on November 15, 2010, the Company received a notice from
the Exchange stating that the Exchange staff determined that the Company had not
timely regained compliance with the Exchange’s continued listing standards in
Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Exchange’s Company
Guide because the Company’s stockholders’ equity is less than $6,000,000 and
that, accordingly, the Company’s common stock was subject to being delisted from
the Exchange. In accordance with Sections 1009(d) and 1203 of the Exchange’s
Company Guide, the Company appealed the determination and requested a hearing
before the Exchange’s Listing Qualifications Panel. The hearing was scheduled to
occur on January 20, 2011.
Item
8.01
Other
Events.
On
January 21, 2011, the Company issued a press release announcing the foregoing.
The reader is advised to read this press release in its entirety. A copy of the
press release is attached hereto as Exhibit 99.1 and incorporated by reference
herein.
Item
9.01
Financial Statement
and Exhibits
(d)
Exhibits.
99.1 Press
Release.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
Cytomedix,
Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ Martin P. Rosendale
|
|
|
Martin
P. Rosendale
Chief
Executive Officer
|
|
|
Date: January
21, 2011
Cytomedix (AMEX:GTF)
Historical Stock Chart
From Apr 2024 to May 2024
Cytomedix (AMEX:GTF)
Historical Stock Chart
From May 2023 to May 2024